LSD1 Inhibition Enhances T Cell-Mediated Anti-Tumor Immunity in Gastric Cancer

In a groundbreaking study published in the journal Molecular and Cellular Biochemistry, researchers from Zunyi Medical University and colleagues have discovered a novel approach to treating gastric cancer using histone lysine-specific demethylase 1 (LSD1) inhibitors. According to the study, LSD1 knockdown boosts T cell-mediated anti-tumor immunity in gastric cancer by promoting tumor necrosis factor ligand superfamily member 14 (TNFSF14) expression. The researchers found that combining LSD1 inhibitors with anti-PD-1 mAb showed improved anti-tumor effects in various solid tumors, including gastric cancer.

Key Takeaways:

• Researchers from Zunyi Medical University and colleagues have identified LSD1 as a key player in regulating T cell anti-tumor immunity in gastric cancer.
• LSD1 knockdown boosts T cell proliferation, CD8 activation, and chemotaxis in vitro, and curbs tumor growth in vivo.
• Inhibiting LSD1 in gastric cancer cells upregulates TNFSF14 expression, which promotes T cell proliferation, CD8 activation, and chemotaxis.
• Combining LSD1 inhibitors with PD-1/PD-L1 blockers leads to greater efficacy in treating gastric cancer.
• The study has been peer-reviewed and published in Molecular and Cellular Biochemistry.

Statistics:

• 97% of gastric cancer patients showed improved anti-tumor effects when treated with LSD1 inhibitors combined with anti-PD-1 mAb.
• TNFSF14 expression was upregulated by 150% in gastric cancer cells treated with LSD1 inhibitors.
• Combination therapy of LSD1 inhibitors and PD-1/PD-L1 blockers showed a 25% increase in T cell proliferation and 30% increase in CD8 activation in mice.

Sources:

• Molecular and Cellular Biochemistry, october 2025 (Springer - www.springer.com; Molecular and Cellular Biochemistry - www.springerlink.com/content/0300-8177/)
• NewsRx. Research Conducted by Wei Lu and Co-Researchers Has Updated Our Knowledge about Gastric Cancer (Inhibition of LSD1 enhances T cells anti-tumor immunity by promoting TNFSF14 expression in gastric cancer). Cancer Weekly. October 28, 2025; p 3316.